CXCR4 and glioblastoma: Our study, however, provides evidence for an enhanced survival effect on GBM-bearing mice which were treated with combination between PRX177561 and bevacizumab or sunitinib and represents a significant scientific rationale for clinical evaluation of this combined therapy that targets both VEGF/VEGFRs and CXCL12/CXCR4.